Category NEWS

Celea Therapeutics

Celea Therapeutics Secures $180 Million to Advance Deupirfenidone for Idiopathic Pulmonary Fibrosis Treatment

Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) Celea Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing transformative treatments for people with serious respiratory diseases, today…

Read MoreCelea Therapeutics Secures $180 Million to Advance Deupirfenidone for Idiopathic Pulmonary Fibrosis Treatment
PureTech

PureTech-Founded Celea Therapeutics Raises $180 Million to Accelerate Deupirfenidone Development for IPF

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) PureTech Health plc a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation…

Read MorePureTech-Founded Celea Therapeutics Raises $180 Million to Accelerate Deupirfenidone Development for IPF
AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program

AGC Pharma Chemicals Validates CDMO Facilities Through Scientist.com’s VERIF.i® Program

AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, and AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) for small molecule…

Read MoreAGC Pharma Chemicals Validates CDMO Facilities Through Scientist.com’s VERIF.i® Program
Bureau

Bureau Veritas Agrees to Sell Oil, Petrochemicals, and Coal Testing & Inspection Business Under LEAP | 28 Portfolio Rotation Strategy

In Line With the LEAP | 28 Portfolio Rotation Strategy, Bureau Veritas Signs an Agreement to Sell Its Oil & Petrochemicals and Coal Testing and Inspection Business Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces…

Read MoreBureau Veritas Agrees to Sell Oil, Petrochemicals, and Coal Testing & Inspection Business Under LEAP | 28 Portfolio Rotation Strategy
Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Merck to Acquire Bio-Techne, Expanding Leadership in High-Growth Life Sciences Markets

Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets Merck, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive…

Read MoreMerck to Acquire Bio-Techne, Expanding Leadership in High-Growth Life Sciences Markets
Verici

Verici Dx Receives New York State Approval, Expanding Nationwide Access to the Tutivia™ Kidney Transplant Rejection Test

Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test Verici Dx plc  a developer of advanced clinical diagnostics for organ transplant, announced it has received clinical laboratory accreditation from the New York State…

Read MoreVerici Dx Receives New York State Approval, Expanding Nationwide Access to the Tutivia™ Kidney Transplant Rejection Test
Bionyra Pharma

Bionyra Pharma Launches with Oversubscribed $165 Million Series A to Advance Next-Generation Biologics

Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated inflammatory diseases, today announced the company’s launch…

Read MoreBionyra Pharma Launches with Oversubscribed $165 Million Series A to Advance Next-Generation Biologics